Skip to main content

Table 2 Effect of tranexamic acid on vascular occlusive events (fatal and non-fatal) at 28 days in all patients, stratified by severity and country income level

From: Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial

  TXA Placebo RR (95% CI)
N n (%) N n (%)  
All patients 6359 101 (1.6) 6280 102 (1.6) 0.98 (0.74–1.28)
Severity
Mild/moderate 4066 41 (1.0) 3997 52 (1.3) 0.76 (0.52–1.16)
Severe 2264 60 (2.7) 2247 50 (2.2) 1.19 (0.82–1.73)
Country income
LMIC 4375 50 (1.1) 4330 35 (0.8) 1.41 (0.92–2.17)
HIC 1984 51 (2.6) 1950 67 (3.4) 0.75 (0.52–1.07)